share_log

東証グロ-ス市場250指数は大幅反落、切り返すも大型株につられ下げ幅拡大

The Tokyo Stock Exchange's 250 Gross Market Index fell sharply and expanded its decline due to the pullback of large cap stocks, although it rebounded.

Fisco Japan ·  Jul 24 04:06

Tokyo Stock Exchange Growth Market Index 836.81 -14.26/ trading volume 0.2 billion 98.64 million shares/trading price 132.1 billion yen

Tokyo Stock Exchange Growth Market 250 Index 648.21 -12.69/ trading volume 0.1 billion 62.32 million shares/trading price 90.3 billion yen

Today's growth market fell sharply in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index. The number of rising stocks is 144, the number of falling stocks is 412, and 28 unchanged.

The US stock market fell on the 23rd. The Dow average closed at 40358.09 dollars (-0.14%), the Nasdaq fell 10.22 points (-0.06%) at 17997.35, and the S&P 500 closed at 5555.74, which was 8.67 points lower (-0.16%). There was a strong sense of optimism ahead of the announcement of the company's financial results, and people were close to each other. Furthermore, adjustments awaiting important inflation and economic indicators scheduled to be announced this week continued, and while sales and buying intersected throughout the day, strong buying supported by good financial results and expectations of interest rate cuts remained steady, but the market price turned to a decline towards the end of the game and ended.

In response to a decline in US stocks, etc., trading began with a slight selling advantage in the growth market. There was also a scene where both the Growth Market Index and the Growth Market 250 Index switched back and forth, but when the Nikkei Average depreciated one level in the back market, it became difficult. The depreciation of the yen did not serve as a tailwind, and the decline gradually widened.

Individually, biotechnology-related cell seeds (7776) continued to decline for 5 days, and symbio (4582) fell drastically. At the top of the market capitalization, JTOWER (4485), which had a significant increase the day before, became dominant in sales, and ISPACE <9348>, Wealth Navi <7342>, and Integral <5842> declined. Ibis <9343>, Kokopelli <4167>, and Medicine Counter <5592> are ranked at the top of the price drop rate.

Meanwhile, Ribomic <4591>, which signed a joint research agreement on ophthalmic diseases with the University of Tokyo, was bought, and the AIAI Group <6557>, which had been flooded with purchases using shareholder benefits etc. as materials, surged by over 50% compared to the previous day due to expanded price limits. GENDA <9166 >, ADVENTURE <6030>, and SUNWELLS <9229> were bought at the top of the market capitalization. Modalis (4883), WASH House (6537), and Pixta (3416) rank at the top of the price increase rate.

In addition to JTOWER, ISPACE, and Wealth Navi, Safey (4375) and GMO Financial Gate (4051) fell among stocks that adopted the Tokyo Stock Exchange Growth Market Core Index.


[Top 10 stocks with growth rate and decline rate in the Tokyo Stock Exchange Growth Rate]

・Top 10 price increase rates

|code|stock | current value| day-over-day| previous ratio|

1| 6557|AIAI | 2460| 840| 51.85|

2| 4883|modalis | 102| 30| 41.67|

3| 6537|WASH HOUSE | 493| 80| 19.37|

4| 190A|Chordia | 628| 100| 18.94|

5| 206a|PRISMBiO | 530| 80| 17.78|

6| 4882|Perseus | 708| 100| 16.45|

7| 3416|piksta | 1136| 126| 12.48|

8| 4591|ribomic | 102| 10| 10.87|

9| 5597 | BLUE INNOVE | 1130| 99| 9.60|

10| 9159|WTOKYO | 2557| 201| 8.53|

・Top 10 price drop rates

|code|stock | current value| day-over-day| previous ratio|

1| 9343|ibis | 3810| -555| -12.71|

2| 7776|cellseed | 470| -67| -12.48|

3| 9330|Ageha | 981| -110| -10.08|

4| 4582|SYNBIO PHARMACEUTICAL | 303| -32| -9.55|

5| 6696|truss OP | 642| -62| -8.81|

6| 4167|kokopelli | 495| -45| -8.33|

7| 7094|NEXTONE | 1465| -132| -8.27|

8| 5259|BBDI | 868| -78| -8.25|

9| 4424|Amazon | 449| -40| -8.18|

10| 5592|Medicine Window | 1398| -117| -7.72|

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment